Engene Holdings INC 10-Q quarterly reports

enGene Therapeutics Inc. filed its Form 10-Q for the quarter ended April 30, 2026, detailing financial results, strategic updates including a significant workforce reduction, and progress on its lead drug candidate, detalimogene.

enGene Holdings Inc. reported a significant increase in net loss and R&D expenses for the quarter ended July 31, 2025, as it advances its lead bladder cancer therapy, detalimogene, towards a planned 2026 BLA submission.

enGene Holdings Inc. announced a significant increase in net loss and cash burn for the six months ended April 30, 2025, driven by intensified research and development efforts for its lead bladder cancer therapy, detalimogene, while also addressing internal control deficiencies and expanding its executive team.

enGene Holdings Inc. reports increased R&D spending as it advances its detalimogene program for bladder cancer treatment.

enGene Holdings Inc. reports a net loss of $14.1 million for the three months ended July 31, 2024, driven by increased research and development spending.

enGene Holdings Inc. reports a significant increase in operating expenses, primarily driven by research and development activities, while highlighting progress in its EG-70 clinical trial.

enGene Holdings Inc. reported a net loss of $10.7 million for the first quarter of 2024, while highlighting progress in its clinical development programs and a recent $200 million private placement.